← FDA DRUG APPROVALS

FDA ANDA · ANDA202014

DEBLITANE

norethindrone

Sponsor: NOVAST LABS

APPLICATION
ANDA202014
TYPE
ANDA
ORIGINAL APPROVAL
2013-09-13
LATEST ACTION
2014-08-29
ROUTE
ORAL-28
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

NORETHINDRONEPrescription
NORETHINDRONE 0.35MG · TABLET · ORAL-28

Approval history

2014-08-29Labeling · Supplement 1 · standardAP
2013-09-13OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →